Acetohydroxamic Acid: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Acetohydroxamic Acid. Educational only — not medical advice.

Labeled uses

Acetohydroxamic acid is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. AHA is intended to decrease urinary ammonia and alkalinity, but it should not be used in lieu of curative surgical treatment (for patients with stones) or antimicrobial treatment. Long-term treatment with AHA may be warranted to maintain urease inhibition as long as urea-splitting infection is present. Experience with AHA does not go beyond 7 years. A patient package insert should be distributed to each patient who receives AHA.

Source: FDA labeling via NIH DailyMed (set 6660b616…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.